<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01519947</url>
  </required_header>
  <id_info>
    <org_study_id>ML25754</org_study_id>
    <nct_id>NCT01519947</nct_id>
  </id_info>
  <brief_title>A Study of The Effect of Altitude on Mircera (Methoxy Polyethylene Glycol-Epoetin Beta) Dose Requirements in Patients With Chronic Renal Anemia in Pre-Dialysis or Dialysis</brief_title>
  <official_title>Comparative Study to Assess the Effect of the Altitude on Dose Requirements of Methoxy Polyethylene Glycol-epoetin Beta to Correct Haemoglobin Levels in Chronic Renal Anemia in Pre-dialysis and Dialysis Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <brief_summary>
    <textblock>
      This comparative, open-label, multicenter, parallel-group study will evaluate the effect of
      altitude on dose requirements of Mircera (methoxy polyethylene glycol-epoetin beta) to
      achieve a target haemoglobin concentration of 11-12 g/dL in patients with chronic renal
      anemia in pre-dialysis and dialysis. Four groups of patients, at sea level or an altitude
      above 6'000 feet and in pre-dialysis or dialysis, will receive 50-250 mcg Mircera
      subcutaneously according to local label. Anticipated time on study treatment is 36 weeks.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2012</start_date>
  <completion_date type="Actual">May 2015</completion_date>
  <primary_completion_date type="Actual">May 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dosage required to achieve target haemoglobin concentration of 11-12 g/dL</measure>
    <time_frame>approximately 20 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in haemoglobin concentration</measure>
    <time_frame>from baseline to Month 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients achieving target haemoglobin concentration 11-12 g/dL after 3 and 6 months of treatment</measure>
    <time_frame>approximately 20 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety: Incidence of adverse events</measure>
    <time_frame>approximately 20 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients requiring dose adjustments</measure>
    <time_frame>approximately 20 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of red blood cell transfusions</measure>
    <time_frame>approximately 20 months</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">86</enrollment>
  <condition>Anemia, Kidney Disease, Chronic</condition>
  <arm_group>
    <arm_group_label>Dialysis &gt;6000 feet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dialysis sea level</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Pre-dialysis &gt;6000 feet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Pre-dialysis sea level</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methoxy polyethylene glycol-epoetin beta [Mircera]</intervention_name>
    <description>50-250 mcg sc according to local label</description>
    <arm_group_label>Dialysis &gt;6000 feet</arm_group_label>
    <arm_group_label>Dialysis sea level</arm_group_label>
    <arm_group_label>Pre-dialysis &gt;6000 feet</arm_group_label>
    <arm_group_label>Pre-dialysis sea level</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patients, &gt;/= 18 years of age

          -  Chronic kidney disease stage III-IV or V

          -  Probable start of dialysis within 18 months (pre-dialysis group)

          -  Hemodialysis or peritoneal dialysis in a stable regimen for at least 3 months
             (dialysis group)

          -  Adequate iron status

          -  Females of childbearing potential must agree to use two effective methods of
             contraception during the study and for at least 2 months following the last dose of
             study drug

        Exclusion Criteria:

          -  Failing renal allograft in place

          -  Acute or chronic bleeding within 8 weeks prior to screening

          -  Transfusion of red blood cells within 8 weeks prior to screening

          -  Poorly controlled hypertension, defined as hypertension that needs hospitalization to
             obtain control

          -  History of seizures, hemoglobinopathies and/or severe liver disease

          -  Active malignant disease, except for non-melanoma skin cancer

          -  Immunosuppressive therapy in the 12 weeks prior to screening

          -  Treatment with any other investigational agent or participation in a clinical trial
             within 28 days prior to enrolment

          -  Known hypersensitivity to Mircera (methoxy polyethylene glycol-epoetin beta) or any of
             its excipients

          -  Pregnant or lactating women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Aguascalientes</city>
        <zip>20210</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Delegaci√≥n Coyoacan</city>
        <zip>CP. 04700</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mexicali</city>
        <zip>21100</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mexico City</city>
        <zip>07760</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Morelia</city>
        <zip>58070</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pureto Vallarta</city>
        <zip>48333</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Veracruz</city>
        <zip>91700</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 18, 2012</study_first_submitted>
  <study_first_submitted_qc>January 24, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2012</study_first_posted>
  <last_update_submitted>November 1, 2016</last_update_submitted>
  <last_update_submitted_qc>November 1, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 2, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Chronic Disease</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epoetin Alfa</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>September 8, 2017</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

